Literature DB >> 11923814

Poor prognosis and related factors in adults with Eisenmenger syndrome.

Hideo Oya1, Noritoshi Nagaya, Masaaki Uematsu, Toru Satoh, Fumio Sakamaki, Shingo Kyotani, Nagato Sato, Norifumi Nakanishi, Kunio Miyatake.   

Abstract

BACKGROUND: Little information is available regarding the clinical history and long-term prognosis of patients with Eisenmenger syndrome without diagnosis until adulthood. The purpose of this study was to investigate the long-term prognosis and factors predictive of the prognosis in patients with Eisenmenger syndrome diagnosis in adulthood. METHODS AND
RESULTS: We retrospectively reviewed the clinical data of 106 patients with Eisenmenger syndrome diagnosis in adulthood. Presence of congenital heart defects had neither been noticed nor confirmed with cardiac catheterization until adulthood in most of the patients in our study. After the diagnosis was confirmed, 42 patients died during a mean follow-up period of 7.6 years. The mean survival time from diagnostic catheterization to death was 5.4 years in nonsurvivors. Survival rate was 98% at 1 year, 77% at 5 years, and 58% at 10 years, with the Kaplan-Meier method. Elevated right atrial pressure (>7 mm Hg) and reduced systemic blood flow (<2.9 L/min) were independently associated with increased mortality rate of adults with Eisenmenger syndrome.
CONCLUSION: Patients with Eisenmenger syndrome without diagnosis until adulthood had a poor prognosis. Reduced systemic blood flow and elevated right atrial pressure were associated with high mortality rates in adults with Eisenmenger syndrome.

Entities:  

Mesh:

Year:  2002        PMID: 11923814     DOI: 10.1067/mhj.2002.121267

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome.

Authors:  Song I Yang; Wook Jin Chung; Sung Hwan Jung; Deok Young Choi
Journal:  Pediatr Cardiol       Date:  2012-02-18       Impact factor: 1.655

2.  First successful heart-lung transplantation in Japan: report of a case.

Authors:  Yoshiki Sawa; Goro Matsumiya; Shigefumi Shigemura; Hiroyuki Nishi; Hajime Ichikawa; Masato Minami; Norihide Fukushima; Masayoshi Inoue; Takayoshi Ueno; Akiyoshi Sawabatav; Taichi Sakaguchi; Shunsuke Saito; Meinoshin Okumura
Journal:  Surg Today       Date:  2013-02-20       Impact factor: 2.549

3.  Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism.

Authors:  M G J Duffels; M N van der Plas; S Surie; M M Winter; B Bouma; M Groenink; A P J van Dijk; E Hoendermis; R M F Berger; P Bresser; B J M Mulder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

4.  The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects.

Authors:  Erwin Oechslin; Siegrun Mebus; Ingram Schulze-Neick; Koichiro Niwa; Pedro T Trindade; Andreas Eicken; Alfred Hager; Irene Lang; John Hess; Harald Kaemmerer
Journal:  Curr Cardiol Rev       Date:  2010-11

5.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease.

Authors:  Antonio Lopes; Khalid Alnajashi
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.